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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The role of trivalent chromium in improving glucose tolerance is
well documented. Increased urinary chromium has been reported
in type 2 diabetes mellitus, but it was not clear whether this had
preceded diabetes mellitus, or was caused by it. Aim was to inves 
tigate the relationship between urinary chromium and the degree
of insulin resistance in non diabetic normotensive Saudi adults.
357 healthy adults aged 18–50 years were recruited randomly in
a cross sectional study design. Anthropometric and demographic
information were taken. Insulin, glucose and free fatty acids were
measured in fasting blood samples. Fasting urinary chromium and
creatinine were also determined. Using modified QUICKI, subjects
were labeled as high insulin resistant, or low insulin resistant.
High insulin resistant subjects were matched for age and sex to
low insulin resistant subjects. High insulin resistant subjects had
higher mean BMI (p<0.001), mean waist circumference (p<0.01),
and median urinary chromium (p<0.001) compared to low insulin
resistant subgroup. Higher urinary chromium in high insulin
resistant subgroup indicates a renal lesion leading to chromium
deficiency and possibly diabetes mellitus eventually. Chromium
supplementation might help to protect against the development
of diabetes mellitus in this group of high insulin resistant non dia 
betic Saudi individuals.
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Introduction The role of chromium in maintaining normal glucose tolerance
is well documented.(1–4) A three fold increase in 24 h urinary
chromium in diabetic subjects over values obtained from a normal
control group was reported.(5) More recently, higher mean fasting
urinary chromium was reported in Saudi non-insulin dependent
diabetes mellitus (NIDDM) patients, compared to healthy controls,(6)
and it was suggested that urinary chromium response to glucose
load could be used as an indicator of chromium status.(7) It is not
known whether the increased excretion has started before the
disorder causing deficiency of the element and decreased glucose
tolerance leading to diabetes, or it was due to the effect of diabetes
on the kidney?
Studies have shown that insulin resistance predict the develop-
ment of diabetes in many populations.(8–13) There has been no work
so far on chromium status or serum and urinary levels in insulin
resistant subjects who are not yet diabetic. Therefore, our aim is to
investigate the relationship between the degree of insulin resis-
tance; determined by modified Quantitative Insulin Sensitivity
Check Index (QUICKI);(14,15) and urinary chromium excretion in
normotensive, non-diabetic Saudi individuals in an attempt to
answer the above question.
Materials and Methods
Subjects and study protocol. A cross-sectional study design
was implemented. Healthy subjects aged 18–50 years were
recruited randomly from individuals visiting health centers during
the period between July 2005 and January 2007.
Six health centers (representing the six health sectors of Jeddah)
were chosen randomly. Based on earlier study of insulin resistance
in Saudi diabetic individuals,(16) the sample size to detect differ-
ences between means or medians of anthropometric measurements
and estimated blood indices in high insulin resistance (HIR), and
low insulin resistance (LIR) subgroups was computed using
Power And Precision (Version 2) statistical analysis software by
Biostat, and selecting power of the study as 0.9 (90%). The calcu-
lated sample size was found to be 205. According to population
density; a sample size was then calculated for each centre, and
fractions rounded to nearest whole number. Exclusion criteria
included: reported diabetes (or fasting plasma glucose ≥126 mg/dl
(≥7.0 mmol/l) upon testing), endocrine disorders, hypertension,
reported dyslipidaemia and coronary heart diseases. Hypertension
was defined as a systolic blood pressure >140 mm Hg, or diastolic
blood pressure >90 mm Hg,(17) or current use of antihypertensive
medications. Dyslipidaemia was defined as increased cholesterol
level (total cholesterol level ≥5.2 mmol/l, a low density lipo-
protein-cholesterol (LDL-C) ≥3.36 mmol/l, and/or a high density
lipoprotein-cholesterol (HDL-C) <1.04 mmol/l),(18) and/or increased
level of triglycerides (≥1.7 mmol/l).(19)
An ethical approval was granted by the bioethical and research
committee. Informed consents were obtained from all participants
after explanation of purpose, nature and potential risks of the study.
Recruits were checked for hypertension, and only normotensive
individuals were interviewed for demographic information, and
their anthropometric measurements were taken. Abdominal obesity
was defined as >88 cm in females and >102 cm in males.(20)
Selected subjects were given an appointment for blood and
urine collection while fasting. Collected urine void samples were
processed as described earlier(7) and frozen at –20°C for later
estimation of chromium, while collected blood samples were
immediately placed on ice prior to processing. Glucose was
determined first in separated serum, and subjects showing
hyperglycemia were excluded. Remaining samples were divided
into aliquots and frozen at –70°C for later measurements of insulin
and free fatty acids (FFAs).
The modified QUICKI was calculated as reported earlier
[modified QUICKI = 1/[log (fasting insulin) + log (fasting blood
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glucose) + log (fasting FFA)].(14) Individuals whose samples had
a value outside limits reported for non insulin resistant healthy
subjects by Perseghin et al.(14,15) for modified QUICK, were
labeled HIR. They were matched for age and sex to individuals
from the rest of the study population to obtain the LIR.
Biochemical measurements. Glucose was estimated using
automated enzymatic methods (Dade Behring Inc., Deerfield,
IL) (CV was 1.8% and 3.9% for intra- and inter-batch
respectively). Insulin was estimated in one batch using the ‘electro
chemiluminescence immunoassay’ ‘ECLIA’ on Modular Analytics
E 170 (Elecsys module) immunoassay analyzer, supplied by
Roche Diagnostics GMbH (R&D Systems, Inc., Minneapolis, MN
USA) (CV was 9.7%). All measurements were carried out at the
university hospital biochemistry laboratory. FFAs were estimated
manually in serum using an enzymatic method (Wako Chemicals
GMbH, Neuss, Germany), with intra-, and inter-batch CV being
5.2%, and 9.8% respectively. Urinary chromium was estimated
using a SOLAAR M5 (Thermo Electron, Cambridge, UK) with a
deuterium background corrector and a GF95 graphite furnace with
auto-sampler as described earlier.(21) The intra-assay and inter-
assay coefficients of variation for urinary chromium were found
to be <8% and <12%, respectively. Urine creatinine levels were
measured by a Jaffe based reaction(22) using a commercial kit
(Crescent Diagnostics, Jeddah, KSA).
Statistical methods. Descriptive statistics such as mean ±
SD for normally distributed data or median and inter quartile range
(IQR) for non-normally distributed variables were calculated for
all parameters in the two subgroups. Statistical analysis were
performed using unpaired t test and Mann Whitney U test for
comparison of normally distributed and non normally distributed
parameters respectively, while χ2 test was used to compare
categorical parameters. A statistical computer programme (SPSS)
was used to analyze the data. Significance was assigned at p<0.05.
Results
Three hundred and fifty seven subjects were recruited. Only 209
subjects (76 males and 133 females) satisfied the criteria and
provided required samples. The demographic and anthropometric
characteristics of the selected group are presented in Table 1,
while their biochemical parameters are presented in Table 2.
Using the modified QUICKI and a cut-off point of <0.419, 97
individuals (i.e. 46.4% of total) were identified as having HIR,
including 34 males (35.1%) and 63 females (64.9%). The division
between sexes was not significantly different to that in the group
as a whole (p>0.05).
Matching for age and sex could be done for 90 IR subjects
only. Anthropometric and demographic characteristics of both
groups are presented in Table 3, while biochemical parameters are
presented in Table 4.
The HIR group had significantly higher mean weight, higher
percentage of obese individuals, and higher percentage of subjects
with abdominal obesity.
Despite the fact that samples with high glucose value were
excluded from the start, the mean glucose level of HIR group as a
whole was found to be significantly higher than the corresponding
mean of the LIR group (p<0.05). This did not prevent the
significant increase noted in the median insulin value of HIR
group (p<0.001). Further more, the median FFA value, and the
median urinary chromium level were both significantly higher for
the HIR group (p<0.001 in both cases).
Discussion
Several methods are available to assess insulin sensitivity in
humans, the “gold standard” being the euglycemic hyper-
insulinemic clamp (IS clamp) because it directly measures the
Table 1. Demographic and anthropometric characteristics of the study group
BMI: body mass index, N: number of subjects. Data are presented as mean ± SD, or number and percentage.
Male Female Total
No. of subjects (%) 76 (36.4%) 133 (63.6%) 209 (100%)
Age (yrs) 33.0 ± 10.8 31.3 ± 10.2 31.8 ± 10.4
Weight (Kg) 73.2 ± 16.0 67.2 ± 15.8 69.3 ± 16.1
Height (cm) 168.0 ± 9.5 157.5 ± 7.6 161.3 ± 9.7
BMI (Kg/m2)2 5 . 7 ± 5.3 26.90 ± 6.5 26.44 ± 6.12
BMI classes N (%):
Normal (<25 Kg/m2) 37 (48.7%) 59 (44.4%) 96 (46.0%)
Overweight (25 <30 Kg/m2) 24 (31.6%) 35 (29.3%) 59 (28.2%)
Obese (≥30 Kg/m2) 15 (19.7%) 39 (29.3%) 54 (25.8%)
Waist (cm) 87.2 ± 15.3 82.3 ± 16.4 84.6 ± 17.0
Hip (cm) 98.4 ± 15.9 105.1 ± 14.9 103.3 ± 16.1
Waist: Hip ratio 0.89 ± 0.015 0.78 ± 0.08 0.82 ± 0.15
Family history of diabetes mellitus N (%) 39 (51.3%) 70 (52.6%) 109 (52.1%)
Table 2. Biochemical parameters of the study group
FFA: Free fatty acids, TC: Total cholesterol, TG: Triglycerides, N: number of subjects. Data are
presented as mean ± SD for normally distributed parameters and as median and (IQR) for
non normal distributed ones.
Male Female Total
No. of subjects (%) 76 (36.4%) 133 (63.6%) 209 (100%)
Glucose (mmol/l) 5.6 ± 0.80 5.5 ± 0.80 5.5 ± 0.80
Insulin (mU/l) 7.5 (4.4–14.3) 7.8 (5.7–11.1) 7.7 (5.3–11.5)
FFA (mg/dl) 8.0 (5.3–10.8) 8.8 (6.1–11.6) 8.4 (5.8–11.3)doi: 10.3164/jcbn.10 148
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insulin action on glucose utilization under steady—state condi-
tions.(23) However, this technique is laborious and only applicable
to a small number of subjects.(23) There are a number of other
more practical methods used to evaluate insulin sensitivity in
research and clinical larger scale settings. The most popular
measures; especially among health practitioners in Saudi Arabia;
are the Homeostasis Model Assessment (HOMA-IR), and the
QUICKI [derived from fasting plasma glucose (FPG) and fasting
plasma insulin (FPI) concentrations]. Both correlate reasonably
with the clamp technique,(24,25) but both have limitations also,(25–27)
as both reflect hepatic IR only, not IR at peripheral tissues.(28)
More recently, Perseghin et al.(14) by incorporating fasting
plasma free fatty acid (FFA) concentration into QUICKI, improved
its correlation to the IS clamp and its discriminatory power in
cases of mild insulin resistant states.(15) Insulin resistance at
adipose tissue will lead to elevated plasma FFA. Therefore,
inclusion of FFA into the QUICKI formula can be beneficial and
increase its detection power by including those subjects with
peripheral IR, especially that lipolysis is more sensitive to insulin
than glucose utilization,(29) and dysfunctional regulation of lipolysis
was established in insulin resistant subjects.(30) Furthermore, a
small increase in plasma FFA concentration in healthy individuals
is reported to induce insulin resistance.(31) For these reasons, this
method was chosen as a measure of insulin resistance in our
population, and the earlier reported cut off point(14,15) was adopted.
No significant difference was found between the two
groups in the family medical history. Even though a high
percentage of subjects (>50%) in both study groups reported a
family history of diabetes, finding no significant difference between
the percentages of the two study groups was surprising. Higher
insulin resistance is reported for off springs of diabetic parents,(10)
therefore it was expected to find a higher incidence of diabetes
in families of HIR group. Other factors must have been behind the
increased IR in the HIR group.
More obese and overweight individuals in the Insulin
resistant group. Insulin resistance generally rises with in-
creasing body fat content.(32) This was noted in our study, as
individuals in the high insulin resistant group had significantly
higher mean weight, mean BMI, mean waist and hip circum-
ference (Table 3) compared to LIR group. Furthermore, a higher
percentage of HIR subjects suffered from abdominal obesity, as
indicated by waist circumference >88 cm for females, and
>102 cm for males. Thus, it can be suggested that obesity in the
Saudi population is one of the main factors in the pathogenesis of
insulin resistance.
The biochemical profiles of the two study groups differed
significantly. The means or medians of almost all biochemical
parameters were significantly higher in the selected HIR group.
This is expected if the method of selection is efficient, which
justifies our use of the modified QUICKI equation. More work is
needed to determine appropriate cut of point for Saudi subjects
with different degrees of obesity.
Significantly higher median urinary chromium in HIR group
is a very important finding. Increased urinary excretion of
chromium is reported in stress,(33) following exercise,(34) as well as
after the ingestion of glucose load.(35) Increase excretion could lead
to deficiency, and hence impaired glucose tolerance. In fact,
diabetes caused by the stress of corticosteroids treatment was
reported to be reversed by chromium supplementation.(33) Increased
excretion is also reported in diabetic patients compared to control
subjects.(5,6) Further more, a correlation between 24 h chromium
excretion and 24 h glucose excretion was reported in type I
diabetic patients.(36) The question to be asked is whether the
increased excretion has started before the onset of the disorder,
thus causing deficiency of the element and decreased glucose
tolerance leading to diabetes, or it was due to the effect of diabetes
Table 3. Anthropometric and demographic characteristics of high insulin resistant (HIR) and low insulin resistant
(LIR) subgroups using modified QUICKI
BMI: body mass index, N: number of subjects. Continuous variables were compared by t test for normally distributed
and Mann Whitney U test for non normally distributed parameters. Categorical data were compared by χ2 test.
HIR (n = 90) LIR (n = 90) p
Age (years) 32.4 ± 9.9 31.7 ± 9.5 0.66
Weight (Kg) 74.1 ± 17.9 66.5 ± 14.0 0.002
BMI (Kg/m2)2 9 . 0 ± 7.1 25.6 ± 4.6 0
BMI classes N (%):
Normal (<25 Kg/m2) 26 (28.89%) 41 (45.6%)
Overweight (25–29.9 Kg/m2) 25 (27.78%) 34 (37.8%) 4.29 × 10−3
Obese (≥30 Kg/m2) 39 (43.33%) 15 (16.7%)
Waist (cm) 88.5 ± 16.7 82.2 ± 14.8 0.008
Hip (cm) 105.7 ± 15.9 99.3 ± 14.5 0.006
Waist: Hip ratio 0.84 ± 0.10 0.83 ± 0.11 0.68
Waist >88 cm (F) or >102 cm (M) N (%) 37 (41.1%) 19 (21.1%) 4.3 × 10−3
Family history of diabetes mellitus N (%) 48 (53.3%) 51 (56.7%) 0.69
Table 4. Biochemical parameters of high insulin resistant (HIR) and low insulin resistant (LIR) groups
FFA: Free fatty acids, N: number of subjects, TC: Total cholesterol, TG: Triglycerides. Continuous variables were
compared by t test for normally distributed and Mann Whitney U test for non normally distributed parameters.
Categorical data were compared by χ2 test.
HIR (n = 90) LIR (n = 90) p
Urinary chromium (ngm/mg creatinine) 2.92 (1.5–10.28) 0.55 (0.27–1.38) 0
Glucose (mmol/l) 5.7 ± 0.8 5.4 ± 0.7 0.025
Insulin (mU/l) 11.2 (8.3–14.2) 6.1 (4.2–8.4) 0
Free fatty acids (mg/dl) 10.7 (8.4–13.1) 6.5 (4.8–9.3) 0 J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 167
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on the kidney?
There has been no work so far on chromium status or serum and
urinary levels in insulin resistant subjects any where in the world.
Therefore, our work is the first, as far as we know. Finding
significantly higher median urinary chromium in HIR group might
answer the above question, as our results prove that the increased
excretion exists well before the development of diabetes in our
HIR subjects. As mentioned earlier, insulin resistance predicts the
development of diabetes in many populations.(8–13) However, many
insulin resistant individuals will never develop diabetes, and their
metabolic characteristics may well differ from those who do.
Identifying metabolic abnormalities that predispose to diabetes,
and following the time course with which these abnormalities
change as glucose tolerance worsens is expected to help in
instituting preventative measures against the world wide epidemic
of diabetes. Therefore, our findings are very important, and might
help to change the management of insulin resistance and the
metabolic syndrome in our population.
To conclude, obesity as well as increased urinary chromium
excretion are associated with higher insulin resistance in studied
Saudi population. The use of chromium supplements might be
recommended to prevent; or at least delay; the onset of diabetes.
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BMI body mass index
FFA free fatty acids
FPG fasting plasma glucose
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